As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

A 24-year-old woman from York has become one of the first patients in the world to take part in a pioneering research study ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks ...

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the ...

Arcutis is proud to support Dr. Candrice Heath of the Heath Health Foundation for Education and Research by hosting two experiential learning sessions at its booth focused on Culturally Conscious ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

New Delhi: Accepting the bioequivalence study report for Type 2 Diabetes Mellitus, the Subject Expert Committee (SEC) ...

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and ...